GILENYA Hard capsule Ref.[8575] Active ingredients: Fingolimod

Source: European Medicines Agency (EU)  Revision Year: 2019  Publisher: Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland

Product name and form

Gilenya 0.25 mg hard capsules.

Gilenya 0.5 mg hard capsules.

Pharmaceutical Form

Hard capsule.

Gilenya 0.25 mg hard capsules: Capsule of 16 mm with ivory opaque cap and body, with black radial imprint “FTY 0.25mg” on cap and black radial band on body.

Gilenya 0.5 mg hard capsules: Capsule of 16 mm with bright yellow opaque cap and white opaque body; imprint with black ink, “FTY0.5 mg” on cap and two radial bands imprinted on the body with yellow ink.

Qualitative and quantitative composition

Gilenya 0.25 mg hard capsules: Each 0.25 mg capsule contains 0.25 mg fingolimod (as hydrochloride).

Gilenya 0.5 mg hard capsules: Each 0.5 mg capsule contains 0.5 mg fingolimod (as hydrochloride).

For the full list of excipients, see section 6.1.

Active Ingredient Description
Fingolimod

Fingolimod is a sphingosine 1-phosphate receptor modulator. Fingolimod is metabolised by sphingosine kinase to the active metabolite fingolimod phosphate. By acting as a functional antagonist of S1P receptors on lymphocytes, fingolimod phosphate blocks the capacity of lymphocytes to egress from lymph nodes, causing a redistribution, rather than depletion, of lymphocytes.

List of Excipients

Gilenya 0.25 mg hard capsules

Capsule fill:

Mannitol
Hydroxypropylcellulose
Hydroxypropylbetadex
Magnesium stearate

Capsule shell:

Gelatin
Titanium dioxide (E171)
Yellow iron oxide (E172)

Printing ink:

Shellac (E904)
Iron oxide black (E172)
Propylene glycol (E1520)
Ammonia solution, concentrated(E527)

Gilenya 0.5 mg hard capsules

Capsule fill:

Mannitol
Magnesium stearate

Capsule shell:

Gelatin
Titanium dioxide (E171)
Yellow iron oxide (E172)

Printing ink:

Shellac (E904)
Ethanol, anhydrous
Isopropyl alcohol
Butyl alcohol
Propylene glycol (E1520)
Purified water
Ammonia solution, concentrated (E527)
Potassium hydroxide
Black iron oxide (E172)
Yellow iron oxide (E172)
Titanium dioxide (E171)
Dimethicone

Pack sizes and marketing

Gilenya 0.25 mg hard capsules:

PVC/PVDC/aluminium blister packs containing 28 hard capsules.

PVC/PVDC/aluminium perforated unit dose blister packs containing 7x 1 hard capsules.

Gilenya 0.5 mg hard capsules:

PVC/PVDC/aluminium blister packs containing 7, 28 or 98 hard capsules or multipacks containing 84 (3 packs of 28) hard capsules.

PVC/PVDC/aluminium perforated unit dose blister packs containing 7x 1 hard capsules.

Not all pack sizes may be marketed.

Marketing authorization holder

Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland

Marketing authorization dates and numbers

Gilenya 0.25 mg hard capsules: EU/1/11/677/007-008
Gilenya 0.5 mg hard capsules: EU/1/11/677/001-006

Date of first authorisation: 17 March 2011
Date of latest renewal: 23 November 2015

Drugs

Drug Countries
GILENYA Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, United Kingdom, United States

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.